331-345 of 831
First Episode Psychosis: Improving Patient Outcomes Through Early Intervention
NeuroFrontiersFirst Episode Psychosis: Improving Patient Outcomes Through Early Intervention
Ashley Baker, MSN, PMHNP
Hannah Brown, MD
Investigating the Risk of Schizophrenia Among ADHD Patients with Psychiatric Comorbidities
NeuroFrontiersInvestigating the Risk of Schizophrenia Among ADHD Patients with Psychiatric Comorbidities
Detecting MS Biomarkers: An IgG Antibody Blood Test Offers 90% Accuracy
NeuroFrontiersDetecting MS Biomarkers: An IgG Antibody Blood Test Offers 90% Accuracy
Investigating the Clinical Utility of the Multiple Sclerosis Disease Activity Test
NeuroFrontiersInvestigating the Clinical Utility of the Multiple Sclerosis Disease Activity Test
Andrew Wilner, MD, FACP, FAAN
William A. Kilgo, MD
Adverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
NeuroFrontiersAdverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
Andrew Wilner, MD, FACP, FAAN
Carri Polick, PhD, RN
MS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
NeuroFrontiersMS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
Jennifer Caudle, DO, FACOFP
Mitzi Joi Williams, MD
- advertisement
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
NeuroFrontiersMind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Charles Turck, PharmD, BCPS, BCCCP
Anibal Chertcoff, MD
Examining Emerging Gut Microbiota Biomarkers for MS
NeuroFrontiersExamining Emerging Gut Microbiota Biomarkers for MS
MS in Children: Exploring Biomarker Research Advancements
NeuroFrontiersMS in Children: Exploring Biomarker Research Advancements
Ahmed Abdelhak, MD
Discussing Disparities in MS Care for Underrepresented Populations
NeuroFrontiersDiscussing Disparities in MS Care for Underrepresented Populations
Charles Turck, PharmD, BCPS, BCCCP
Tirisham V. Gyang, MD
Gopika Govindan Kutty, MD
- advertisement
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
NeuroFrontiersDiscussing the Latest in MS Treatment and Disease-Modifying Therapies
Charles Turck, PharmD, BCPS, BCCCP
Jay Avasarala, MD, PhD
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
NeuroFrontiersA New Hope for Patients with MS – The First FDA-Approved Biosimilar
